drugset / Trial / NCT06519578

Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma

NCT06519578

Recruiting 1115 enrolled RenJi Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is a prospective cohort study aimed at comparing the efficacy and safety of RALOX-HAIC and FOLFOX-HAIC in the treatment of hepatocellular carcinoma. It is planned to enroll 1115 patients with BCLC Stage B or C hepatocellular carcinoma, who will receive FOLFOX-HAIC or RALOX-HAIC treatment.

Timeline

Start
2024-08-01
Primary completion
2026-07-31
Completion
2027-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Leucovorin Small molecule 400 mg/m2 Other
Subject Oxaliplatin Small molecule 85 mg/m2 Other
Subject Oxaliplatin Small molecule 100 mg/m2 Other
Subject Raltitrexed Small molecule 3 mg/m2 Other
Subject fluorouracil Small molecule 2400 mg/m2 Other